

2016-2020 U.S. Tumor Marker Testing Market: Supplier Shares by Test, Country Volume and Sales Segment Forecasts, Innovative Technologies, Instrumentation Review, Competitive Strategies, Emerging Opportunities

https://marketpublishers.com/r/29CF7308E39EN.html

Date: May 2016 Pages: 620 Price: US\$ 7,840.00 (Single User License) ID: 29CF7308E39EN

Abstracts

Complete report \$9,800. DataPack (test volumes, sales forecasts, supplier shares) \$6,400.

VPGMarketResearch.com's new report is a strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines trends in the US cancer diagnostics markets; reviews current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor markers and market segment; profiles leading market players and potential entrants; and suggests alternative business expansion strategies for suppliers. Rationale The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion. Business Opportunities and Strategic Recommendations- Specific new product development opportunities with potentially significant market appeal during the next five years.- Design criteria for new products.- Alternative market penetration strategies. Potential market entry barriers and risks.Cancer Diagnostic Tests Over 200 current and emerging assays



including: ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.**Market Segmentation Analysis**

Sales and market shares of major suppliers, by individual cancer diagnostic test.

Five-year test volume and sales forecasts for major cancer diagnostic tests by market segment, including:

Hospitals

Commercial/Private Laboratories

Physician Offices/Group Practices- Cancer Clinics- Comprehensive market segmentation analysis, including reviewof the market dynamics, structure, size, growth and major suppliers.

Cancer statistics, etiology and recent developments.

Current and Emerging Products

Review of over 200 current and emerging cancer diagnostic tests, including:

Biochemical Markers

Oncogenes

Growth Factors

Hormones

Colony Stimulating Factors



Lymphokines

Immunohistochemical Stains, and others.

Analysis of major immunoassay analyzers used forcancer diagnostic testing, including their operating characteristics, features and selling prices.

Technology Review- Assessment of monoclonal antibodies, immunoassays, DNAprobes, biochips/microarrays, chromosome analysis, IT,artificial intelligence, flow cytometry, biosensors, and other technologies and their potential applications for cancer diagnostic testing.- Review of competing/complementing technologies, includingCT, MRI, NMR, PET and photonics spectroscopy.- Extensive listings of over 500 companies, universities and research centers developing new cancer diagnostic tests and detection technologies.**Competitive Assessments**Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborativearrangements, and new products in R D.

Contains 620 pages and 103 tables



Contents

1. INTRODUCTION

2. WORLDWIDE MARKET OVERVIEW

- 1. MARKET OVERVIEW
- 2. WORLDWIDE MARKET STRUCTURE
- 3. WORLDWIDE MARKET SIZE AND GROWTH

3. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

- A. Reagent Kits and Test Systems/Panels
- B. Instrumentation
- C. Computers, Software and Automation
- D. Auxiliary Products

4. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

5. ALTERNATIVE MARKET PENETRATION STRATEGIES

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies

6. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges

7. WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

A. Cancer Statistics and Etiology

2016-2020 U.S. Tumor Marker Testing Market: Supplier Shares by Test, Country Volume and Sales Segment Forecast...




- 1. BREAST CANCER
- 2. LUNG CANCER
- 3. COLON AND RECTUM CANCER
- 4. PROSTATE CANCER
- 5. STOMACH CANCER
- 6. LEUKEMIA
- 7. LYMPHOMA
- 8. ORAL CANCER
- 9. SKIN CANCER
- **10. UTERINE CANCER**
- 11. OVARIAN CANCER
- 12. BLADDER CANCER
- B. Major Current And Emerging Cancer Diagnostic Tests
 - 1. INTRODUCTION
 - 2. TUMOR MARKER CLASSIFICATION
 - 3. ACTH
 - 4. ALPHA FETOPROTEIN (AFP)
 - 5. BETA 2 MICROGLOBULIN
 - 6. CA 15 3/27.29
 - 7. CA 199
 - 8. CA 125
 - 9. CALCITONIN
 - 10. CARCINOEMBRIONIC ANTIGEN (CEA)
 - 11. ESTROGEN AND PROGESTERONE RECEPTORS
 - 12. FERRITIN
 - 13. GASTRIN
 - 14. HUMAN CHORIONIC GONADOTROPIN (HCG)
 - 15. INSULIN
 - 16. NSE
 - 17. OCCULT BLOOD
 - 18. PAP SMEAR/HPV
 - 19. PROSTATIC ACID PHOSPHATASE (PAP)
 - 20. PROSTATE SPECIFIC ANTIGEN (PSA)
 - 21. SQUAMOUS CELL CARCINOMA ANTIGEN (SCC)
 - 22. T AND B LYMPHOCYTES
 - 23. TDT
 - 24. THYROGLOBULIN
 - 25. TISSUE POLYPEPTIDE ANTIGEN (TPA)
 - 26. BIOCHEMICAL TUMOR MARKERS



27. ONCOGENES Abl/abl bcr AIB1 BCL2 BRCA1 CD44 C-fos C-myb C-myc CYP 17 **ErbB** HPC1 Nmyc P40 P51 P53 PIK3CA PTI1 Ras Reg Sis Src 28. POLYPEPTIDE GROWTH FACTORS **Basic Fibroblast Growth Factor** Beta TGF Cachectin (TNT) Calmodulin **ECFR** Nerve Growth Factor (NGF) Epidermal Growth Factor (EGF) **Ornithine Decarboxylase** Transferrin Transforming Growth Factor Alpha **29. ECTOPIC HORMONES 30. COLONY STIMULATING FACTORS 31. LYMPHOKINES** Alpha Interferon **B** Cell Growth Factors

B Cell Growth Factor (BCGF)





Gamma Interferon Interleukin 1 (IL1) Macrophage Activating Factor **32. IMMUNOHISTOCHEMICAL STAINS 33. EMERGING TUMOR MARKERS** NAcetylglucosamine Actin Alpha Actin Antineuronal Antibodies 7B2 B72.3 Bax BCD F9 BLCA 4 Blood Group Antigens A, B, H CA CA 72 4/TAG 72 CA CA 242 CA 549 CAM CAR 3 Cathepsin D Chromogranin A and B Cluster 1 Antigen Cluster 5/5A Antigen CTA CU18 DR 70 DU AN2 Endometrial Bleeding Associated Factor Endostatin **Epithelial Membrane Antigen** Feulgen Hydrolysis Fibronectin FSH (1 >3) Lfucosyltransferase Releasing Peptide (GRP) Gastrin GDCFP 15



Glucagon Glycoamines H23 Her 2 Human Carcinoma Antigen HPA HSP27 **Intermediate Filaments** Cytokeratins/CK18/Cyfra 21 1 Desmin **Gliofibrillary Acid Protein** Neurofilaments Vimentin KA **Kinases KP16D3** LAI Leukocyte Common Antigen Lewis Antigens Lysophosphatidic Acid (LPA) Ma 695/Ma MABDF3 MAG ME1 Minactivin MN/CA9 MSA Mucin Cancer Antigen (MCA) Multiple Tumor Suppressor Myosin **NEA 130** NMP22 OA 519 **Opioid Peptides** P glycoprotein Pancreatic Oncofetal Antigen (POA) **Placental Lactogen PR92** Proliferative Index, Ki 67



Px **RB** Inactivation/Deletion Ret SCCL Selectin Sialic Acid Sialyl SSEA 1/SLX **SN10** Somatostatin TA 90 TABA Tachykinin TAG TPS Troponin Tubulin VCAM VEGF Villen

C. Cancer Diagnostic Testing Instrumentation Review and Market Needs

- D. Current and Emerging Cancer Diagnostic Technologies
 - 1. MONOCLONAL AND POLYCLONAL ANTIBODIES
 - 2. IMMUNOASSAYS
 - 3. MOLECULAR DIAGNOSTICS
 - 4. CHROMOSOME ANALYSIS
 - a. Chronic Myelogenous Leukemia (CML)
 - b. Acute Myeloid Leukemia (AML)
 - c. Acute Lymphoblastic Leukemia (ALL)
 - d. Malignant Lymphomas Lymphoid Malignancies
 - e. Chronic Lymphocytic Leukemia (CLL)
 - f. Solid Cancers
 - g. Chromosomal Translocation and Oncogenes
 - 5. ARTIFICIAL INTELLIGENCE
 - 6. FLOW CYTOMETRY
 - 7. TW DIMENSIONAL GEL ELECTROPHORESIS (2 DGE)
 - 8. BIOSENSORS
 - 9. COMPETING/COMPLEMENTING TECHNOLOGIES
- E. Personal Testing



8. USA CANCER DIAGNOSTICS MARKET

- A. Executive Summary
- B. Business Environment
- C. Market Structure

D. Market Size, Test Volume and Sales Forecasts by Market Segment, Major Supplier Sales and Market Shares by Test

9. COMPETITIVE PROFILES

Abbott

- AdnaGen/Alere
- Agilent Technologies
- Applied Gene Technologies
- Arca Biopharma
- Beckman Coulter/Danaher
- **Becton Dickinson**
- **Biomedical Diagnostics**
- bioMerieux
- **Bio-Rad**
- CellSearch
- Cepheid
- Correlogic Systems/Vermillion
- **Decode Genetics**
- Diadexus
- Diagnocure
- Diasorin
- **Eiken Chemical**
- Elitech Group
- Enterix
- Enzo Biochem
- **Epigenomics**
- Exact Sciences
- Fujirebio
- Guided Therapeutics
- Hologic/Genrobe
- Kreatech/Leica
- Kyowa Medex
- Mackay Life Sciences



Myriad Genetics OncoLab Ortho Clinical Diagnostics Panacea Pharmaceuticals Polartechnics Polymedco PreMD Qiagen **Quest Diagnostics Radient Pharmaceuticals** Roche Scienion Sequenom **Siemens Healthcare** Takara Bio **Targeted Diagnostics & Therapeutics** Tosoh Thermo Veridex Wako Pure Chemicals Wallac/PE Zila

10. APPENDIX: MAJOR UNIVERSITIES AND RESEARCH CENTERS DEVELOPING CANCER DIAGNOSTIC TECHNOLOGIES AND APPLICATIONS



List Of Tables

LIST OF TABLES

Tumor Marker Classification Major Companies Developing or Marketing ACTH Tests Major Companies Developing or Marketing AFP Tests Major Companies Developing or Marketing Beta 2 Microglobulin Tests Major Companies Developing or Marketing CA 15 3/27.29 Tests Major Companies Developing or Marketing CA 199 Tests Major Companies Developing or Marketing CA 125 Tests Major Companies Developing or Marketing Calcitonin Tests Major Companies Developing or Marketing CEA Tests Major Companies Developing or Marketing Estrogen Receptor Tests Major Companies Developing or Marketing Progesterone Receptor Tests Major Companies Developing or Marketing Ferritin Tests Major Companies Developing or Marketing Gastrin Tests Major Companies Developing or Marketing HCG Tests Major Companies Developing or Marketing Insulin Tests Major Companies Developing or Marketing NSE Tests Major Companies Developing or Marketing Occult Blood Tests Major Companies Developing or Marketing PAP Smear/HPV Tests Major Companies Developing or Marketing PAP Tests Major Companies Developing or Marketing PSA Tests Major Companies Developing or Marketing Lymphocyte Subclassification Tests **Biochemical Markers Potential Applications In Cancer Diagnosis Oncogenes Potential Applications In Cancer Diagnosis** Major Companies Developing or Marketing Oncogene Tests Growth Factors Potential Applications In Cancer Diagnosis Colony Stimulating Factors Potential Applications in Cancer Diagnosis Lymphokines Potential Applications In Cancer Diagnosis Immunohistochemical Stains Potential Applications in Cancer Diagnosis Executive Summary Table: U.S., Total Tumor Marker Test Volume and Sales Forecast By Market Segment U.S., Estimated New Cancer Cases and Deaths U.S., Estimated Cancer Death Rates Per 100, 000 Population U.S., Laboratories Performing Tumor Marker Tests by Market Segment U.S., Hospital Laboratories Performing Tumor Marker Tests by Bed Size U.S., Commercial/Private Laboratories Performing Tumor Marker Tests By Annual Test



Volume

- U.S., Physician Office Laboratories Performing Tumor Marker Tests by Practice Size
- U.S., Total Tumor Marker Test Volume Forecast by Market Segment
- U.S., All Market Segments Major Tumor Marker Test Volume Forecast
- U.S., Hospital Laboratories Major Tumor Marker Test Volume Forecast by Test
- U.S., Commercial/Private Laboratories Major Tumor Marker Test Volume Forecast
- U.S., Physician Offices/Group Practices Major Tumor Marker Test Volume Forecast
- U.S., Cancer Clinics Major Tumor Marker Test Volume Forecast by Test
- U.S., Total Tumor Marker Sales Forecast by Market Segment
- U.S., All Market Segment Major Tumor Marker Sales Forecast by Test
- U.S., Hospital Laboratories Major Tumor Marker Sales Forecast by Test
- U.S., Commercial/Private Laboratories Major Tumor Marker Sales Forecast by Test
- U.S., Physician Offices/Group Practices Major Tumor Marker Sales Forecast by Test
- U.S., Cancer Clinics Major Tumor Marker Sales Forecast by Test
- U.S., ACTH Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., AFP Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Beta 2 Microglobulin Test Volumeand Diagnostics Sales Forecast by Market Segment

- U.S., CA 15 3/27.29 Test Volumeand Diagnostics Sales Forecast by Market Segment
- U.S., CA 199 Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., CA 125 Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., Calcitonin Test Volumeand Diagnostics Sales Forecast by Market Segment
- U.S., Cathepsin Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., CEA Test Volume and Diagnostics Sales by Market Segment
- U.S., Chromogranin Test Volumeand Diagnostics Sales Forecast by Market Segment
- U.S., Colon specific Antigen Test Volume And Diagnostics Sales Forecast by Market Segment

U.S., Cytokeratins Test Volume And Diagnostics Sales Forecast by Market Segment U.S., Estrogen Receptor Test Volume And Diagnostics Sales Forecast by Market Segment

- U.S., Ferritin Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., Gastrin Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., HCG Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., Insulin Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., Interferons Test Volume And Diagnostics Sales Forecast by Market Segment
- U.S., Interleukins Test Volume And Diagnostics Sales Forecast by Market Segment

U.S., Lymphocyte Subtyping Test Volumeand Diagnostics Sales Forecast by Market Segment

U.S., NSE Test Volume and Diagnostics Sales Forecast by Market Segment



U.S., Nucleolar Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Occult Blood Test Volume And Diagnostics Sales Forecast by Market Segment

U.S., Oncogenes Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Pancreatic Oncofetal Antigen Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., PAP Smear Test Volume and Diagnostics Sales Forecast by Market Segment U.S., Parathyroid Hormone Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Progesterone Receptor Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., PAP Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., PSA Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., S 100 Protein Test Volumeand Diagnostics Sales Forecast by Market Segment

U.S., Serotonin Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Sialic Acid Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Squamous Cell Carcinoma Antigen Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., TDT Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Thymidine Kinase Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Thyroglobulin Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., TPA Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Total Tumor Marker Sales By Major Supplier

U.S., ACTH Testing Market Diagnostics Sales by Major Supplier

U.S., AFP Testing Market Diagnostics Sales by Major Supplier

U.S., Beta 2 Migroblolulin Testing Market Diagnostics Sales by Major Supplier

U.S., CA 15 3/27.29 Testing Market Diagnostics Sales by Major Supplier

U.S., CA 199 Testing Market Diagnostics Sales by Major Supplier

U.S., CA 125 Testing Market Diagnostics Sales by Major Supplier

U.S., CEA Testing Market Diagnostics Sales by Major Supplier

U.S., Ferritin Testing Market Diagnostics Sales by Major Supplier

U.S., HCG Testing Market Diagnostics Sales by Major Supplier

U.S., Insulin Testing Market Diagnostics Sales by Major Supplier

U.S., Parathyroid Hormone Testing Market Diagnostics Sales by Major Supplier

U.S., PAP Testing Market Diagnostics Sales by Major Supplier

U.S., Progesterone Receptor Testing Market Diagnostics Sales by Major Supplier

U.S., PSA Testing Market Diagnostics Sales by Major Supplier



I would like to order

Product name: 2016-2020 U.S. Tumor Marker Testing Market: Supplier Shares by Test, Country Volume and Sales Segment Forecasts, Innovative Technologies, Instrumentation Review, Competitive Strategies, Emerging Opportunities

Product link: https://marketpublishers.com/r/29CF7308E39EN.html

Price: US\$ 7,840.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/29CF7308E39EN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature ___

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below



and fax the completed form to +44 20 7900 3970